Le Lézard
Classified in: Health, Business
Subjects: TNM, PET

Ampersand Announces Successful Exit of Roadrunner Pharmacy


WELLESLEY, Mass., Aug. 10, 2017 /PRNewswire/ --  Ampersand Capital Partners announced today that portfolio company Roadrunner Pharmacy has been acquired by Vets First Choice.  In 2012, Ampersand invested in a partial recapitalization that was Roadrunner's first and only institutional equity financing, consistent with Ampersand's strategy of partnering with founder owned and operated companies.  Over the last five years, Roadrunner experienced significant growth in revenues and EBITDA, leading to this successful exit. 

Ampersand Capital Partners logo

Based in Phoenix, Arizona, Roadrunner is a leading provider of customized prescription medication to veterinary clinics and pet owners across the US.  Licensed in all 50 states, Roadrunner employs more than 250 pharmacists, pharmacy technicians, sales and service professionals.  The pharmacy has built its reputation on delivering high quality compounded medications in a wide range of proprietary dose forms and exceptional customer service, including free next-day shipping. 

"We're enthusiastic to enable access to specialty pharmacy services via our prescription management platform for veterinarians and patients," said Benjamin Shaw, Founder and CEO of Vets First Choice.  "The combination of these capabilities helps practices streamline workflow, improve service, and enhance client communication."

About Vets First Choice

Vets First Choice is a leading provider of technology-enabled healthcare services for companion and equine veterinary practitioners. Founded in 2010, the company partners with veterinarians to create insight into gaps in patient care and offers professionalized pro-active prescription management to drive client engagement and improve compliance. Its services result in better prescription compliance, increased client engagement, and improved practice revenues and profitability. For more information, please visit www.vetsfirstchoice.com.

About Ampersand Capital Partners

Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector.  Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships.  Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.  Additional information about Ampersand is available at www.ampersandcapital.com.

SOURCE Ampersand Capital Partners


These press releases may also interest you

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....

at 10:00
Driving is the leading cause of work-related death each year in the United States, with nearly 40% of deaths on the job occurring on American roads according to the U.S. Bureau of Labor Statistics. A major contributing factor to road deaths each...

at 10:00
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according...



News published on and distributed by: